Rigshospitalet
Copenhagen, 2100, Denmark
NCT Number: NCT02776241
The objective of this study is to measure the influence of both short term water restriction and high water intake on total kidney volume, measured by Magnetic Resonance Imaging (MRI) scan in Autosomal Dominant Polycystic Kidney Disease (ADPKD) patients.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Copenhagen, 2100, Denmark
Patients will be randomized to either water restriction for 3 hours or high water intake (20 ml/kg) for 1 hour. Before intervention and after intervention patients will have an MRI scan of the kidneys to measure the total kidney volume (TKV) (differentiated in cortex, medulla and cyst volume). The objective is to identify whether water restriction or high water load will change the TKV. Secondly investigators will analyze different biomarkers (aldosterone, renin, vasopressin/copeptin, urine- and blood-osmolarity) before and after the intervention.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline and 3 hours
Time frame: Baseline and 3 hours
Time frame: Baseline and 3 hours
Time frame: Baseline and 3 hours
Time frame: Baseline and 3 hours
Rigshospitalet, Denmark
Other
Effect of Water Intake and Water Restriction on Total Kidney Volume in Autosomal Dominant Polycystic Kidney: The HYDRA Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03717883
ADPKD, Abnormalities, Multiple
Chapel Hill, North Carolina, United States
View Trial DetailsNCT05521191
ADPKD, Abnormalities, Multiple
Mesa, Arizona, United States
View Trial DetailsNCT06085807
ADPKD, Abnormalities, Multiple
San Francisco, California, United States
View Trial DetailsNCT03203642
ADPKD, Abnormalities, Multiple
La Jolla, California, United States
View Trial Details